Duchenne News Tags: PTC Therapeutics

On March 31, 2026, PTC Therapeutics, Inc. provided an update to the Duchenne community following the withdrawal of the ataluren (Translarna) approval application in the United States. To view their...

On February 12, 2026, PTC Therapeutics, Inc. announced that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy...

On August 11, 2025, PTC Therapeutics shared a community update about the status of the Ataluren FDA filing, the first potential therapy specifically for individuals with nonsense mutation Duchenne. To...

PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for Translarna™.

On May 20, 2024, PTC Therapeutics announced that the European Commission (EC) has decided not to adopt the CHMP’s negative opinion of January 24, 2024 on the annual renewal of...

PTC plans to re-submit an NDA for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy.

A letter to the Duchenne community from PTC Therapeutics about current regulatory processes for Translarna.

PTC Therapeutics, Inc. shares a community letter to the Duchenne community

On June 20, 2022, PTC Therapeutics, Inc. announced they will be hosting a call to review topline results from Study 041 for Translarna.